PE20211757A1 - Formas cristalinas y formas de sal de un inhibidor de cinasa - Google Patents
Formas cristalinas y formas de sal de un inhibidor de cinasaInfo
- Publication number
- PE20211757A1 PE20211757A1 PE2021000862A PE2021000862A PE20211757A1 PE 20211757 A1 PE20211757 A1 PE 20211757A1 PE 2021000862 A PE2021000862 A PE 2021000862A PE 2021000862 A PE2021000862 A PE 2021000862A PE 20211757 A1 PE20211757 A1 PE 20211757A1
- Authority
- PE
- Peru
- Prior art keywords
- forms
- relates
- compound
- crystalline forms
- kinase inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a formas cristalinas de la base libre del inhibidor de c-Met: N-(4-fluorofenil)-N-(4-((7-metoxi-6- (metilcarbamoil)quinolin-4-il)oxi)fenil)ciclopropano-1,1- dicarboxamida, (Compuesto 1). La invencion tambien se refiere a formas cristalinas de sales del Compuesto 1. La invencion tambien se refiere a composiciones farmaceuticas que comprenden los polimorfos solidos de la base libre y sales del Compuesto 1. La invencion se refiere ademas a metodos para tratar una enfermedad, trastorno o sindrome mediado al menos en parte por la modulacion de la actividad in vivo de una proteina cinasa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779430P | 2018-12-13 | 2018-12-13 | |
| US201962856469P | 2019-06-03 | 2019-06-03 | |
| PCT/US2019/065972 WO2020123800A1 (en) | 2018-12-13 | 2019-12-12 | Crystalline forms and salt forms of a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211757A1 true PE20211757A1 (es) | 2021-09-07 |
Family
ID=69160358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000862A PE20211757A1 (es) | 2018-12-13 | 2019-12-12 | Formas cristalinas y formas de sal de un inhibidor de cinasa |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US12017995B2 (es) |
| EP (2) | EP4631505A3 (es) |
| JP (2) | JP7509779B2 (es) |
| KR (2) | KR20250103803A (es) |
| CN (1) | CN113329790A (es) |
| AU (2) | AU2019395419B2 (es) |
| BR (1) | BR112021011333A2 (es) |
| CA (1) | CA3122840A1 (es) |
| CL (1) | CL2021001537A1 (es) |
| CO (1) | CO2021007613A2 (es) |
| CR (1) | CR20210375A (es) |
| DK (1) | DK3894012T3 (es) |
| ES (1) | ES3052838T3 (es) |
| FI (1) | FI3894012T3 (es) |
| GE (1) | GEP20247596B (es) |
| HR (1) | HRP20251122T1 (es) |
| HU (1) | HUE072868T2 (es) |
| IL (2) | IL320433A (es) |
| LT (1) | LT3894012T (es) |
| MA (1) | MA54458B1 (es) |
| MD (1) | MD3894012T2 (es) |
| MX (1) | MX2021006951A (es) |
| PE (1) | PE20211757A1 (es) |
| PH (1) | PH12021551356A1 (es) |
| PL (1) | PL3894012T3 (es) |
| PT (1) | PT3894012T (es) |
| RS (1) | RS67216B1 (es) |
| SG (1) | SG11202105949RA (es) |
| SI (1) | SI3894012T1 (es) |
| SM (1) | SMT202500346T1 (es) |
| TW (1) | TWI852963B (es) |
| WO (1) | WO2020123800A1 (es) |
| ZA (1) | ZA202103844B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4647127A3 (en) * | 2018-01-26 | 2025-12-17 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| BR112021024300A2 (pt) * | 2019-06-03 | 2022-01-11 | Exelixis Inc | Formas de sais cristalinas de um inibidor de quinase |
| BR112022021712A2 (pt) * | 2020-04-30 | 2022-12-06 | Exelixis Inc | Processos para a preparação de um inibidor de quinase |
| BR112023001792A2 (pt) | 2020-07-31 | 2023-04-11 | Exelixis Inc | Combinações para o tratamento de câncer |
| KR20230104186A (ko) * | 2020-11-05 | 2023-07-07 | 엑셀리시스, 인코포레이티드 | 키나제 억제제의 약제학적 조성물 |
| CN112650176B (zh) * | 2020-12-22 | 2022-08-30 | 天能化工有限公司 | 一种盐酸解析开停车工序的dcs控制方法 |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
| CA3240202A1 (en) | 2021-12-22 | 2023-06-29 | Kirsten Phizackerley | Crystalline forms and salt forms of a kinase inhibitor |
| CN116751161A (zh) * | 2023-06-28 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | 喹啉类化合物及其制备方法、药物组合物及医药用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2925655T3 (es) * | 2003-09-26 | 2022-10-19 | Exelixis Inc | Moduladores c-Met y métodos de uso |
| CA2604238C (en) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| BRPI0920261A8 (pt) | 2008-10-14 | 2016-01-19 | Xi Ning | Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica |
| KR20250123237A (ko) | 2009-01-16 | 2025-08-14 | 엑셀리시스, 인코포레이티드 | 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CN114507282B (zh) | 2012-10-04 | 2025-05-16 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| HUE053069T2 (hu) | 2013-05-02 | 2021-06-28 | Anaptysbio Inc | Programozott halál-1 (PD-1) ellen irányuló ellenanyagok |
| US10501418B2 (en) | 2014-02-14 | 2019-12-10 | Exelixis, Inc. | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| JP7166292B2 (ja) | 2017-05-26 | 2022-11-07 | エグゼリクシス， インコーポレイテッド | Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法 |
| EP4647127A3 (en) * | 2018-01-26 | 2025-12-17 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| BR112021024300A2 (pt) * | 2019-06-03 | 2022-01-11 | Exelixis Inc | Formas de sais cristalinas de um inibidor de quinase |
-
2019
- 2019-12-12 WO PCT/US2019/065972 patent/WO2020123800A1/en not_active Ceased
- 2019-12-12 GE GEAP201915695A patent/GEP20247596B/en unknown
- 2019-12-12 AU AU2019395419A patent/AU2019395419B2/en active Active
- 2019-12-12 HR HRP20251122TT patent/HRP20251122T1/hr unknown
- 2019-12-12 MD MDE20211022T patent/MD3894012T2/ro unknown
- 2019-12-12 PE PE2021000862A patent/PE20211757A1/es unknown
- 2019-12-12 PL PL19836338.4T patent/PL3894012T3/pl unknown
- 2019-12-12 BR BR112021011333-9A patent/BR112021011333A2/pt unknown
- 2019-12-12 ES ES19836338T patent/ES3052838T3/es active Active
- 2019-12-12 IL IL320433A patent/IL320433A/en unknown
- 2019-12-12 SM SM20250346T patent/SMT202500346T1/it unknown
- 2019-12-12 CA CA3122840A patent/CA3122840A1/en active Pending
- 2019-12-12 FI FIEP19836338.4T patent/FI3894012T3/fi active
- 2019-12-12 LT LTEPPCT/US2019/065972T patent/LT3894012T/lt unknown
- 2019-12-12 SI SI201930963T patent/SI3894012T1/sl unknown
- 2019-12-12 KR KR1020257021669A patent/KR20250103803A/ko active Pending
- 2019-12-12 HU HUE19836338A patent/HUE072868T2/hu unknown
- 2019-12-12 CN CN201980090041.5A patent/CN113329790A/zh active Pending
- 2019-12-12 RS RS20250909A patent/RS67216B1/sr unknown
- 2019-12-12 MX MX2021006951A patent/MX2021006951A/es unknown
- 2019-12-12 IL IL283860A patent/IL283860B2/en unknown
- 2019-12-12 PT PT198363384T patent/PT3894012T/pt unknown
- 2019-12-12 EP EP25183289.5A patent/EP4631505A3/en active Pending
- 2019-12-12 EP EP19836338.4A patent/EP3894012B1/en active Active
- 2019-12-12 MA MA54458A patent/MA54458B1/fr unknown
- 2019-12-12 CR CR20210375A patent/CR20210375A/es unknown
- 2019-12-12 US US17/312,658 patent/US12017995B2/en active Active
- 2019-12-12 SG SG11202105949RA patent/SG11202105949RA/en unknown
- 2019-12-12 DK DK19836338.4T patent/DK3894012T3/da active
- 2019-12-12 JP JP2021533537A patent/JP7509779B2/ja active Active
- 2019-12-12 KR KR1020217021734A patent/KR102828472B1/ko active Active
- 2019-12-13 TW TW108145868A patent/TWI852963B/zh active
-
2021
- 2021-06-04 ZA ZA2021/03844A patent/ZA202103844B/en unknown
- 2021-06-09 PH PH12021551356A patent/PH12021551356A1/en unknown
- 2021-06-10 CO CONC2021/0007613A patent/CO2021007613A2/es unknown
- 2021-06-11 CL CL2021001537A patent/CL2021001537A1/es unknown
-
2023
- 2023-12-27 JP JP2023221085A patent/JP7783870B2/ja active Active
-
2024
- 2024-05-07 US US18/657,052 patent/US20240300897A1/en active Pending
-
2025
- 2025-09-22 AU AU2025234277A patent/AU2025234277A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211757A1 (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa | |
| CO2022016323A2 (es) | Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo | |
| MX2020013726A (es) | Compuestos antagonistas de pcsk9. | |
| CY1124257T1 (el) | N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA | |
| AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
| CY1123801T1 (el) | Παραγωγα αρωματικου σουλφοναμιδιου | |
| MX2023000085A (es) | Compuestos antiproliferativos y metodos para utilizarlos. | |
| HRP20251184T1 (hr) | Spojevi za liječenje poremećaja ovisnih o kinazi | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| MX2024006689A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| CL2020003101A1 (es) | Sales de sepiapterina farmacéuticamente aceptables. | |
| MX350898B (es) | Sal de malato de n(4-{[6,7-bis(metiloxi) quinolin-4-il]oxi}fenil)- n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer. | |
| CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
| CU20170026A7 (es) | Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf | |
| CL2021003205A1 (es) | Formas de sales cristalinas de un inhibidor de cinasas | |
| UY30244A1 (es) | Un proceso para preparar derivados de tetrahidroquinolina | |
| UY30460A1 (es) | Compuestos terapéuticos | |
| JOP20210338A1 (ar) | نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد | |
| CL2024002623A1 (es) | Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2. | |
| UY38345A (es) | Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g | |
| AR102457A1 (es) | Compuestos para usarse en el tratamiento antihelmíntico | |
| EA202191620A1 (ru) | Твердые формы, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и его соли, и содержащие их композиции и способы их применения | |
| EA201992744A1 (ru) | Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей | |
| PE20240223A1 (es) | Composiciones farmaceuticas de un inhibidor de cinasa |